U39-33954-12163
2 vaccinations
1 coded response
15 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 937 / CA
- Registered
- 2021-03-19
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-02-25
Dose 1 — Pfizer-BioNTech
-
2021-03-18
Dose 2 — Pfizer-BioNTech
-
2021-03-19
Registered in v-safe
-
2021-03-19
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-03-20
- 2021-03-21
- 2021-03-22
- 2021-03-23
- 2021-03-24
- 2021-03-26
- 2021-04-01
- 2021-04-08
- 2021-04-15
- 2021-04-22
- 2021-04-29
- 2021-06-17
- 2021-09-16
-
2022-03-18
Survey response — 12 months, dose 2MedDRA: Abortion spontaneous, Menstruation irregular — Feeling: GoodFree text: Miscarriage and irregular periods.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-25 | Pfizer-BioNTech | |
| 2 | 2021-03-18 | Pfizer-BioNTech |
Free text
Release 11 — 12 months, dose 2
Symptoms: Miscarriage and irregular periods.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Abortion spontaneous | · | · | ✓ |
| SD | Menstruation irregular | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release